Anixa Biosciences, Inc. (ANIX)

Price$2.70

Value ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-54.57%

Price vs S&P 500 (4W)-18.98%

VGM Score28.15

Market Capitalization$90.53M

All Metrics

Book Value / Share (Quarterly)$0.45

P/TBV (Annual)14.95x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.21

Price vs S&P 500 (YTD)-24.40%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-1090.48%

EPS (TTM)$-0.32

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$-0.32

EPS (Annual)$-0.34

ROI (Annual)-72.07%

Gross Margin (Annual)97.00%

Net Profit Margin (5Y Avg)-2904.81%

Cash / Share (Quarterly)$0.42

ROA (Last FY)-67.95%

EBITD / Share (TTM)$-0.34

ROE (5Y Avg)-51.70%

Operating Margin (TTM)-1219.05%

Cash Flow / Share (Annual)$-0.22

P/B Ratio6.00x

P/B Ratio (Quarterly)6.51x

Net Income / Employee (Annual)$-2,731,700

EV / Revenue (TTM)423.71x

Net Interest Coverage (TTM)-9.44x

ROA (TTM)-62.53%

EPS Incl Extra (Annual)$-0.34

Current Ratio (Annual)8.08x

Quick Ratio (Quarterly)11.49x

3-Month Avg Trading Volume0.13M

52-Week Price Return3.45%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.26

P/S Ratio (Annual)431.07x

Asset Turnover (Annual)0.01x

52-Week High$5.46

Operating Margin (5Y Avg)-3024.30%

EPS Excl Extra (Annual)$-0.34

Tangible BV CAGR (5Y)36.29%

26-Week Price Return-38.64%

Quick Ratio (Annual)7.71x

13-Week Price Return-11.18%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.18x

Enterprise Value$88.98M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)4.92%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.45x

Pretax Margin (Annual)-4728.57%

Cash / Share (Annual)$0.46

3-Month Return Std Dev47.48%

Gross Margin (5Y Avg)88.48%

Net Income / Employee (TTM)$-2,577,000

ROE (Last FY)-72.07%

Net Interest Coverage (Annual)-9.44x

EPS Basic Excl Extra (Annual)$-0.34

P/FCF (TTM)19.68x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.32

Receivables Turnover (Annual)0.00x

ROI (TTM)-65.55%

P/S Ratio (TTM)431.07x

Pretax Margin (5Y Avg)-2941.13%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.26

Price vs S&P 500 (52W)-24.76%

Year-to-Date Return-13.46%

5-Day Price Return-3.23%

EPS Normalized (Annual)$-0.34

ROA (5Y Avg)-48.99%

Net Profit Margin (Annual)-4671.90%

Month-to-Date Return-10.00%

EBITD / Share (Annual)$-0.36

Operating Margin (Annual)-5243.33%

LT Debt / Equity (Annual)4.72x

ROI (5Y Avg)-51.70%

LT Debt / Equity (Quarterly)11.73x

EPS Basic Excl Extra (TTM)$-0.32

P/TBV (Quarterly)14.95x

P/B Ratio (Annual)8.97x

Inventory Turnover (TTM)0.89x

Pretax Margin (TTM)-1100.00%

Book Value / Share (Annual)$0.46

Price vs S&P 500 (13W)-20.93%

Beta0.62x

P/FCF (Annual)69.10x

Revenue / Share (TTM)$0.00

ROE (TTM)-65.55%

52-Week Low$2.44

vGradeD

mGradeD

vgmGradeD

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.10

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ANIXAnixa Biosciences, Inc.	D	—	D	$2.70
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Anixa Biosciences develops cancer vaccines and immunotherapies targeting major oncology indications including breast, ovarian, lung, colon, and prostate cancers. The company operates two primary therapeutic segments: cancer vaccines for treatment and prevention, and CAR-T therapies including lira-cel for ovarian cancer through subsidiary Certainty Therapeutics. Anixa's approach addresses critical unmet needs in oncology through multiple immunotherapy modalities.